In addition, CD40 deficiency has been shown to reduce the burden of atherosclerosis.[51,52] These findings suggest that decades of research on the CD40-CD40L interaction and atherosclerosis have identified a promising immune-therapy target for this disease with high probability. This evidence concerns the gene CD40 and atherosclerosis.